Hicran ERCAN, Muhterem POLAT, EMİNE TAMER, BAŞAK YALÇIN, Pınar ÖZTAŞ, Dilek ÇALIŞKAN, Güneş GÜR, Nuran ALLI

Verrülü hastalarda serum çinko düzeyinin araştırılması

Bu çalışmada verrülü hastaların serum çinko düzeylerini araştırarak verrü ile serum çinko düzeyi arasındaki ilişkiyi göstermek istedik. Çalışmamız prospektif kontrollü yönteme uygun olarak planlandı. Çalışmaya verrü tanısı konulan 75 hasta ile, 38 sağlıklı kontrol dahil edildi. Verilerin istatistiksel değerlendirmesinde ki-kare, Mann-Whitney, t-test, Levene testleri kullanıldı. P

Anahtar Kelimeler:

Bağışıklık, Siğiller, İleriye dönük çalışma, Çinko

Evaluation of serum zinc levels in patients with verru

In this study, the aim was to highlight the relation between verru and zinc by evaluating the serum zinc levels of patients with verru. The study was designed as a prospective controlled study. 75 patients diagnosed with verru and 38 healty subjects were included. Data were analysed using chisquare, Mann-Whitney, T-test, Levene Test. P<0.05 was considered to be statistically significant. Serum zinc levels of the patient group was 723.8 μgr/L, and the control group’s was 835.87 μgr/L. Serum zinc levels of the patient group was found to be statistically significantly lower than the control group’s. No significant difference was detected in the number of verru and the duration of the disease of the patients with low and normal zinc levels. The relation between the number of verru and the duration of the disease was not statistically significant. Serum zinc levels did not differ due to age and gender in both groups. It is well known that cellular immunity plays the major role in the host defense against HPV. Zinc is essential for all of the organisms and bears important roles in the immune system. It was observed that the changes in the immune system was reversed by zinc replacement. There are problems like the treatments of the verru are ineffective and many of them are destructive, and the recurrence is high. Oral zinc sulphate is easily available, cheap and easily applied treatment, so it might be a safe treatment option.

Keywords:

Immunity, Warts, Prospective Studies, Zinc,

PDF

___

AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Dermatology in General Medicine. 6th Edition. Mc Graw-Hill Book Company, New York 2003;2: 2119-31.
2. Odom RB, Jams WD, Berger TG. Warts. In: Andrew’s Disease of the Skin. 9th Edition. WB Saunders Company. Philadelphia, 2000; 509-20.
3. Jablonska S. Warts. In: Clinical Dermatology; DJ Demis, Lippincott Book Company, Philadelphia, 1992; 3, U14.
4. Schwartz JR, Marsh RG, Draelos ZD. Zinc and skin health: overview of physiology and pharmacology. Dermatol Surg 2005;31: 837-47.
5. Krause-Jarres JD. Pathogenesis and symptoms of zinc deficiency. Am Clin Lab 2001;20: 17-22.
6. Tüzün Y, Arzuhal N. Çinko Eksikliği ile ilgili Deri Hastalıkları. Dermatose 2004;2: 84-91.
7. Perafan-Riveros-C, Franca LF, Alves AC, Sanches JA Jr. Acrodermatitis enteropathica: Case roport and review of the literature. Pediatr Dermatol 2002;19: 426-31.
8. Al Gurairi FT, Al-Waiz M, Sharquie KE. Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial. Br J Dermatol 2002;146: 423-31.
9. Ho E. Zinc deficiency, DNA damage and cancer risk. J Nutr Biochem 2004;15: 572-8.
10. Bhatnagar S, Natchu UC. Zinc in child health and disease. Indian J Pediatr 2004;11: 991-5.
11. Cuevas LE, Koyanagi A. Zinc and infection. Ann Trop Paediatr 2005;25: 149-60.
12. Roberts S, Ashmole I, Sheehan TM, Davies AH, Gallimore PH. Human papillomavirus type1 E4 protein is a zinc-binding protein. Virology 1994;202: 865-74.
13. Beerheide W, Bernard Hu, Tan YJ, Ganesan A, Rice WG, Ting AE. Potential drugs against servical cancer: zinc- ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J Natl Cancer Inst 1999;91: 1211-20.